Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex

Journal of Controlled Release

Volumn 121, Issue 1-2, 2007, Pages 91-99

  Chung, Yong Il ^a   Ahn, Kang Min ^b,c   Jeon, Seung Ho ^b   Lee, Seung Young ^a   Lee, Jong Ho ^b   Tae, Giyoong ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Seoul National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Bone graft; Controlled release; Fibrin; Growth factor; Heparin

Indexed keywords

BONE; CALCIUM; COMPLEXATION; HYDROGELS; PHOSPHATES; PROTEINS;

BONE GRAFT; CONTROLLED RELEASE; FIBRIN; GROWTH FACTOR; HEPARIN;

NANOPARTICLES;

ALKALINE PHOSPHATASE; CALCIUM; FIBRIN GLUE; HEPARIN; NANOPARTICLE; PHOSPHATE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE DENSITY; BONE MINERALIZATION; BONE REGENERATION; CALVARIA; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; HYDROGEL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SUSTAINED DRUG RELEASE; X RAY ANALYSIS;

ALKALINE PHOSPHATASE; ANIMALS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE SUBSTITUTES; CALCIUM; DELAYED-ACTION PREPARATIONS; FIBRIN; HEPARIN; HYDROGELS; IMMUNOHISTOCHEMISTRY; LACTIC ACID; NANOPARTICLES; OSTEOCALCIN; PARTICLE SIZE; PHOSPHATES; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SKULL; TRANSFORMING GROWTH FACTOR BETA;

EID: 34547197434     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.05.029     Document Type: Article

References (41)

1. Aaron A.D., and Wiedel J.D. Allograft use in orthopedic surgery. Orthopedics 17 (1994) 41-48
2. Reynolds M.A., Aichelmann-Reidy M.E., Branch-Mays G.L., and Gunsolley J.C. The efficacy of bone replacement grafts in the treatment of periodontal osseous defects. A systematic review. Ann. Periodontol 8 (2003) 227-265
3. Arrington E.D., Smith W.J., Chambers H.G., Bucknell A.L., and Davino N.A. Complications of iliac crest bone graft harvesting. Clin. Orthop. Relat. Res. 329 (1996) 300-309
4. Bos G.D., Goldberg V.M., Zika J.M., Heiple K.G., and Powell A.E. Immune responses of rats to frozen bone allografts. J. Bone Joint Surg. Am. 65 (1983) 239-246
5. Urist M.R. Bone: formation by autoinduction. Science 150 (1965) 893-899
6. Iwasaki M., Le A.X., and Helms J.A. Expression of Indian hedgehog, bone morphogenetic protein 6 and gli during skeletal morphogenesis. Mech. Dev. 69 (1997) 197-202
7. Herr G., Hartwig C.H., Boll C., and Kusswetter W. Ectopic bone formation by composites of BMP and metal implants in rats. Acta. Orthop. Scand. 67 (1996) 606-610
8. Kawasaki K., Aihara M., Honmo J., Sakurai S., Fujimaki Y., Sakamoto K., Fujimaki E., Wozney J.M., and Yamaguchi A. Effects of recombinant human bone morphogenetic protein-2 on differentiation of cells isolated from human bone, muscle, and skin. Bone 23 (1998) 223-231
9. Datamonitor, Market dynamics: bone substitutes and growth factors - can BMPs become the new gold standard?, London NW3 5JJ, DMHC1812, December 2002.
10. Burg K.J., Porter S., and Kellam J.F. Biomaterial developments for bone tissue engineering. Biomaterials 21 (2000) 2347-2359
11. Geiger M., Li R.H., and Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug Deliv. Rev. 55 (2003) 1613-1629
12. Boden S.D., Martin Jr. G.J., Morone M.A., Ugbo J.L., and Moskovitz P.A. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine 24 (1999) 1179-1185
13. Mumper R.J., Huffman A.S., Puolakkainen P.A., Bouchard L.S., and Gombotz W.R. Calcium-alginate beads for the oral delivery of transforming growth factor-β1 (TGF-β1): stabilization of TGF-β1 by the addition of polyacrylic acid within acid-treated beads. J. Control. Release 30 (1994) 241-251
14. Sakiyama-Elbert S.E., and Hubbell J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release 65 (2000) 389-402
15. Kim H.D., and Valentini R.F. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J. Biomed. Mater. Res. 59 (2002) 573-584
16. Sasaki T., and Watanabe C. Stimulation of osteoinduction in bone wound healing by high-molecular hyaluronic acid. Bone 16 (1995) 9-15
17. Saito N., Okada T., Horiuchi H., Ota H., Takahashi J., Murakami N., Nawata M., Kojima S., Nozaki K., and Takaoka K. Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers. Bone 32 (2003) 381-386
18. Boyan B.D., Lohmann C.H., Somers A., Niederauer G.G., Wozney J.M., Dean D.D., Carnes Jr. D.L., and Schwartz Z. Potential of porous poly-d,l-lactide-co-glycolide particles as a carrier for recombinant human bone morphogenetic protein-2 during osteoinduction in vivo. J. Biomed. Mater. Res. 46 (1999) 51-59
19. Sung H.J., Meredith C., Johnson C., and Galis Z.S. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials 25 (2004) 5735-5742
20. Chung Y.I., Tae G., and Yuk S.H. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors. Biomaterials 27 (2006) 2621-2626
21. Chung Y.I., Lee S.Y., and Tae G. The effect of heparin on the gellation of Pluronic F-127 hydrogel. Colloid Surf. A: Physicochem. Eng. Aspects 284 (2006) 480-484
22. Ruppert R., Hoffmann E., and Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur. J. Biochem. 237 (1996) 295-302
23. Zhao B., Katagiri T., Toyoda H., Takada T., Yanai T., Fukuda T., Chung U.I., Koike T., Takaoka K., and Kamijo R. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J. Biol. Chem. 281 (2006) 23246-23253
24. Peprotech Human BMP-2 ELISA Development Kit 900-K225 (www.peprotech.com/pdf/900-K255%20Human%20BMP-2%20EDK%20Lot%200305255.pdf)
25. The calvarial defect model of rats was prepared according to a method described below. The animals were anesthetized via an intraperitoneal injection with a cocktail of xylazine (Rompun®, 20 mg/ml, Bayer Korea Ltd., Korea) and ketamine hydrochloride (Ketara®, 100 mg/ml, Yuhan Corp, Korea) (1:4 volume mixture, dosage 0.1 ml/100 g body weight). After shaving the scalp hair, a longitudinal incision was made in the midline of cranium from nasal bone to the posterior nuchal line, and the periosteum was elevated to expose the surface of the parietal bone. Using a 8 mm surgical trephine (Ace Surgical supply, Brockton, USA) and small carbide round bur in low-rotational speed drill, calvarial critical size defect (CSD) with an 8 mm diameter was created. To excise exactly the defect out of the cranium for later evaluation, the long diameter of defect was located along the sagittal suture of calvaria. The cutting was done in unique thickness of calvarial depth under the magnification with operating microscope (Zeiss, Germany), and the defect was filled with the prepared implants.
26. 2): the area of newly formed bone within the boundaries of newly formed tissue which consisted with mineralized bone, fibrovascular tissue and marrow.•% Bone marrow: percentage of marrow space with fatty vacuole and marrow cells which is surrounded by bone trabecula.Reference for these parameters includesS.J. Hong, C.S. Kim, D.K. Han, I.H. Cho, U.W. Jung, S.H. Choi, C.K. Kim, K.S. Cho, The effect of a fibrin-fibronectin/beta-tricalcium phosphate/recombinant human bone morphogenetic protein-2 system on bone formation in rat calvarial defects, Biomaterials 27 (2006) 3810-3816.
27. Arakawa T., Wen J., and Philo J.S. Stoichiometry of heparin binding to basic fibroblast growth factor. Arch. Biochem. Biophys. 308 (1994) 267-273
28. Hollinger J.O., Schmitt J.M., Buck D.C., Shannon R., Joh S.P., Zegzula H.D., and Wozney J. Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration. J. Biomed. Mater. Res. 43 (1998) 356-364
29. Hong L., Tabata Y., Yamamoto M., Miyamoto S., Yamada K., Hashimoto N., and Ikada Y. Comparison of bone regeneration in a rabbit skull defect by recombinant human BMP-2 incorporated in biodegradable hydrogel and in solution. J. Biomater. Sci. Polym. Ed. 9 (1998) 1001-1014
30. Ahn S.H., Kim C.S., Suk H.J., Lee Y.J., Choi S.H., Chai J.K., Kim C.K., Han S.B., and Cho K.S. Effect of recombinant human bone morphogenetic protein-4 with carriers in rat calvarial defects. J. Periodontol 74 (2003) 787-797
31. Miki T., and Imai Y. Osteoinductive potential of freeze-dried, biodegradable, poly (glycolic acid-co-lactic acid) disks incorporated with bone morphogenetic protein in skull defects of rats. Int. J. Oral Maxillofac. Surg. 25 (1996) 402-406
32. Schmoekel H., Schense J.C., Weber F.E., Gratz K.W., Gnagi D., Muller R., and Hubbell J.A. Bone healing in the rat and dog with nonglycosylated BMP-2 demonstrating low solubility in fibrin matrices. J. Orthop. Res. 22 (2004) 376-381
33. Piattelli A., Scarano A., Corigliano M., and Piattelli M. Effects of alkaline phosphatase on bone healing around plasma-sprayed titanium implants: a pilot study in rabbits. Biomaterials 17 (1996) 1443-1449
34. Owen T.A., Aronow M., Shalhoub V., Barone L.M., Wilming L., Tassinari M.S., Kennedy M.B., Pockwinse S., Lian J.B., and Stein G.S. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J. Cell Physiol. 143 (1990) 420-430
35. Hosseinkhani H., Hosseinkhani M., Khademhosseini A., and Kobayashi H. Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold. J. Control. Release 117 (2007) 380-386
36. Gadeau A.P., Chaulet H., Daret D., Kockx M., Daniel-Lamaziere J.M., and Desgranges C. Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury. J. Histochem. Cytochem. 49 (2001) 79-86
37. Jeon O., Ryu S.H., Chung J.H., and Kim B.S. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J. Control. Release 105 (2005) 249-259
38. Lee J.S., Go D.H., Bae J.W., Lee S.J., and Park K.D. Heparin conjugated polymeric micelle for long-term delivery of basic fibroblast growth factor. J. Control. Release 117 (2007) 204-209
39. Tae G., Scatena M., Stayton P.S., and Hoffman A.S. PEG-cross-linked heparin is an affinity hydrogel for sustained release of vascular endothelial growth factor. J. Biomater. Sci. Polym. Ed. 17 (2006) 187-197
40. Schense J.C., Bloch J., Aebischer P., and Hubbell J.A. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. Nat. Biotechnol. 18 (2000) 415-419
41. Taylor S.J., and Sakiyama-Elbert S.E. Effect of controlled delivery of neurotrophin-3 from fibrin on spinal cord injury in a long term model. J. Control. Release 116 (2006) 204-210